Ran Wei-Jie, Xu Lan-Ping, Zhang Xiao-Hui, Chang Ying-Jun, Mo Xiao-Dong, Sun Yu-Qian, Huang Xiao-Jun, Wang Yu
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Collaborative Innovation Center of Hematology, Peking University, Beijing 100044, China.
Curr Oncol. 2025 May 22;32(6):294. doi: 10.3390/curroncol32060294.
It is reported that AML with RUNX1 mutations is associated with poorer response to conventional chemotherapy, lower rates of complete remission (CR), leukemia-free survival (LFS), and overall survival (OS). We aimed to evaluate the prognostic impact of RUNX1 mutations following allogeneic hematopoietic stem cell transplantation (allo-HSCT) by comparing clinical outcomes in AML patients with and without RUNX1 mutations. We retrospectively analyzed 91 AML patients (33 RUNX1+ and 58 RUNX1-) who received their first HSCT at Peking University People's Hospital. The median age of the cohort was 38 years (range: 6-64), with 73 patients (80%) receiving Haploidentical HSCT and 18 patients (20%) receiving sibling-matched allo-HSCT. In univariate analyses, no significant differences in survival outcomes were observed. For the RUNX1-mutation group and RUNX1-wild-type group, the 2-year cumulative incidence of relapse (CIR) was (12.6% vs. 7.6%, = 0.472), the 2-year non-relapse mortality (NRM) rate was (9.6% vs. 7.2%, = 0.747), the 2-year LFS was (77.8% vs. 85.2%, = 0.426), and the 2-year OS rate was (85.9% vs. 92.7%, = 0.397). We did not observe any negative impact of RUNX1 mutations on clinical outcomes, suggesting that allo-HSCT (especially Haplo-HSCT) may mitigate the adverse prognostic influence of RUNX1 mutations in AML.
据报道，伴有RUNX1突变的急性髓系白血病（AML）对传统化疗的反应较差，完全缓解（CR）率、无白血病生存率（LFS）和总生存率（OS）较低。我们旨在通过比较有和没有RUNX1突变的AML患者的临床结局，评估异基因造血干细胞移植（allo-HSCT）后RUNX1突变的预后影响。我们回顾性分析了91例在北京大学人民医院接受首次HSCT的AML患者（33例RUNX1+和58例RUNX1-）。该队列的中位年龄为38岁（范围：6-64岁），73例患者（80%）接受单倍体HSCT，18例患者（20%）接受同胞匹配的allo-HSCT。在单因素分析中，未观察到生存结局有显著差异。对于RUNX1突变组和RUNX1野生型组，2年累积复发率（CIR）为（12.6%对7.6%，P = 0.472），2年非复发死亡率（NRM）为（9.6%对7.2%，P = 0.747），2年LFS为（77.8%对85.2%，P = 0.426），2年OS率为（85.9%对92.7%，P = 0.397）。我们未观察到RUNX1突变对临床结局有任何负面影响，这表明allo-HSCT（尤其是单倍体HSCT）可能减轻RUNX1突变对AML的不良预后影响。
